**Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomized double-blinded comparative crossover study**

Krishnakumar IM1\*, Asha Jaja-Chimedza2, Ashil Joseph1, Abhilash Balakrishnan1, Balu Maliakel1, Andrew G. Swick2

1*R & D Centre Akay Natural Ingredients, Cochin, Kerala, India, 683561*

2*Life Extension, 3600 W Commercial Blvd, Fort Lauderdale, FL, 33309, United States of America*

**Table S1**. Demographic, biochemical and hematological details of the participants.

|  |  |
| --- | --- |
| **Parameter** |  |
| No. of volunteers | 15 (M = 12; F = 3) |
| Age (years) | 39.13 ± 11.40 |
| BMI (Kg/m2) | 24.37 ± 1.53 |
| **Hematology** |  |
| *Hemoglobin (g/dL)* | 15.62 ± 1.83 |
| *Total leukocyte count (cells/cumm)* | 7004.00 ± 1230.17 |
| *Total RBC count (million/cumm)* | 5.54 ± 0.47 |
| *Platelet (lakhs/cumm)* | 2.46 ± 0.40 |
| *Neutrophils (%)* | 57.27 ± 5.95 |
| *Lymphocytes (%)* | 35.00 ± 5.62 |
| *Eosinophil’s (%)* | 3.20 ± 0.68 |
| *Monocytes (%)* | 4.53 ± 1.25 |
| **Biochemical** |  |
| *ALT (U/L)* | 37.07 ± 7.78 |
| *AST (U/L)* | 22.73 ± 5.13 |
| *ALP (U/L)* | 66.40 ± 12.77 |
| *Bilirubin (mg/dL)* | 0.48 ± 0.16 |
| *Cholesterol (mg/dL)* | 173.67 ± 20.98 |
| *Triglycerides (mg/dL)* | 114.47 ± 15.83 |
| *HDL (mg/dL)* | 58.60 ± 6.00 |
| *LDL (mg/dL)* | 94.07 ± 3.56 |
| *VLDL (mg/dL)* | 22.89 ± 3.17 |
| *Creatinine (mg/dL)* | 0.73 ± 0.11 |

HDL – High-density lipoprotein, LDL – Low-density lipoprotein, VLDL – Very low density lipoprotein, ALT – Alanine aminotransferase, AST – Aspartate aminotransferase, ALP – Alkaline phosphatase, RBC – Red blood cell, BMI – Body mass index, M – Male, F – Female.